{"disease":{"id":"advanced-nonhaematologic-malignancies","name":"advanced nonhaematologic malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03780517","title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT03328494","title":"Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}